Research programme: antibacterials - Microbia

Drug Profile

Research programme: antibacterials - Microbia

Alternative Names: Anti-Biofilm therapeutics; Antibacterials research programme - Microbia

Latest Information Update: 31 Jul 2006

Price : $50

At a glance

  • Originator Harvard Medical School
  • Developer Dartmouth Medical School; Whitehead Institute for Biomedical Research
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 31 Jul 2006 No development reported - Preclinical for Bacterial infections in USA (unspecified route)
  • 12 Jun 2003 This programme is still in active development
  • 04 Dec 2000 This programme is available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top